Vanda says anxiety drug failed main goal of late — stage study, puts program on hold
Oct 14 (Reuters) — Vanda Pharmaceuticals said on Wednesday its experimental drug for social anxiety disorder failed the main goal of a late-stage study, prompting the company to put the program on hold pending further analysis of the data. Shares of the biopharmaceutical company were down about 17% in extended trading.